Evidence map›Paper›PMID 41788799›Full record

ReviewFrontiers in pharmacology2026

Interplay between flaviviruses and the interferon response: mechanisms of immune evasion and therapeutic implications.

Jiayin Han, Yue Yin, Jing Yuan

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jiayin HanDepartment of Infectious Diseases, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Yue YinShenzhen Key Laboratory of Pathogen and Immunity, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated with Southern University of Science and Technology, Shenzhen, China.
Jing YuanDepartment of Infectious Diseases, The Affiliated Hospital of Southwest Medical University, Luzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The genus Orthoflavivirus encompasses a group of medically significant arthropod-borne viruses, such as dengue virus (DENV), Japanese encephalitis virus West Nile virus Zika virus (ZIKV), and others, which pose persistent global public health threats. The host interferon (IFN) system constitutes a pivotal first line of defense against these viral infections. However, orthoflaviviruses have evolved a remarkable array of sophisticated strategies to antagonize both the induction and signaling pathways of type I and III IFNs. This review systematically summarizes the mechanisms by which orthoflaviviruses evade the IFN response, primarily by employing viral proteins to target key host factors in pattern recognition receptor signaling pathways (e.g., RIG-I, MDA5, MAVS, TBK1, STING, IRF3) and the JAK-STAT signaling cascade (e.g., STAT1, STAT2, IFNAR1). Furthermore, we highlight the critical and complex roles of IFNs at the placental and blood-brain barriers (BBB), the primary sites for transplacental transmission and neuroinvasion. At these barriers, IFNs play a dual role: they exert essential antiviral effects to restrict viral replication, but may also contribute to immunopathology. The delicate balance of IFN responses determines the outcomes of congenital infection and neurological diseases. Finally, we discuss the therapeutic potential of harnessing the IFN pathway, while also acknowledging the challenges and need for further

Indexed as

blood-brain barrierinnate immunityorthoflavivirusplacental barriertype III interferontype I interferonviral antagonism

Identifiers

PMID41788799
PMCPMC12956798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.